메뉴 건너뛰기




Volumn 15, Issue 4, 2017, Pages e80-e81

Nivolumab-Induced Colitis Treated by Infliximab

Author keywords

[No Author keywords available]

Indexed keywords

INFLIXIMAB; METHYLPREDNISOLONE; NIVOLUMAB; PREDNISOLONE; GASTROINTESTINAL AGENT; IMMUNOLOGIC FACTOR; IMMUNOLOGICAL ANTINEOPLASTIC AGENT;

EID: 85008205589     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2016.09.017     Document Type: Article
Times cited : (56)

References (5)
  • 1
    • 84944937210 scopus 로고    scopus 로고
    • Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
    • 1 Borghaei, H., Paz-Ares, L., Horn, L., et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373 (2015), 1627–1639.
    • (2015) N Engl J Med , vol.373 , pp. 1627-1639
    • Borghaei, H.1    Paz-Ares, L.2    Horn, L.3
  • 2
    • 84931083080 scopus 로고    scopus 로고
    • Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
    • 2 Weber, J.S., D'Angelo, S.P., Minor, D., et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 16 (2015), 375–384.
    • (2015) Lancet Oncol , vol.16 , pp. 375-384
    • Weber, J.S.1    D'Angelo, S.P.2    Minor, D.3
  • 3
    • 84969710115 scopus 로고    scopus 로고
    • Managing immune checkpoint-blocking antibody side effects
    • 3 Postow, M.A., Managing immune checkpoint-blocking antibody side effects. Am Soc Clin Oncol Educ Book, 2015, 76–83.
    • (2015) Am Soc Clin Oncol Educ Book , pp. 76-83
    • Postow, M.A.1
  • 4
    • 84877038380 scopus 로고    scopus 로고
    • Ipilimumab-induced acute severe colitis treated by infliximab
    • 4 Pagès, C., Gornet, J.M., Monsel, G., et al. Ipilimumab-induced acute severe colitis treated by infliximab. Melanoma Res 23 (2013), 227–230.
    • (2013) Melanoma Res , vol.23 , pp. 227-230
    • Pagès, C.1    Gornet, J.M.2    Monsel, G.3
  • 5
    • 84966267366 scopus 로고    scopus 로고
    • Cancer immunotherapy with anti-CTLA-4 monoclonal antibodies induces an inflammatory bowel disease
    • 5 Marthey, L., Mateus, C., Mussini, C., et al. Cancer immunotherapy with anti-CTLA-4 monoclonal antibodies induces an inflammatory bowel disease. J Crohns Colitis 10 (2016), 395–401.
    • (2016) J Crohns Colitis , vol.10 , pp. 395-401
    • Marthey, L.1    Mateus, C.2    Mussini, C.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.